Enginprime Medical secures $12M Series A to advance its percutaneous vascular device through Chinese registration and early overseas trials
Executive summary: Enginprime Medical closed a $12 million Series A financing led by Qiming Venture Partners. The capital will fund the company's China NMPA registration trial and early-stage overseas clinical studies, advancing its percutaneous vascular device toward market approval.
Who is involved: Enginprime Medical, Qiming Venture Partners (lead investor), and existing shareholders.
Likely next: Initiation of the China registration trial and patient enrollment in overseas early-stage studies, with subsequent milestones potentially triggering further financing discussions.
Enginprime Medical announced the close of a $12 million Series A financing round exclusively led by Qiming Venture Partners. The proceeds are earmarked for funding the company's China registration trial and overseas early-stage clinical development of its percutaneous vascular technology. This round reflects sustained venture interest in China‑based medtech innovation despite a broader slowdown in early‑stage funding.
Timeline
- — Enginprime Medical Closes $12M Series A Financing (PR Newswire)
Analysis — what this means
Sectors affected
- Medical device manufacturing
- Percutaneous vascular interventions
Regulatory implications
- China NMPA device registration trial required for market clearance
- Overseas early-stage clinical development aimed at FDA IDE or CE Mark feasibility
Sources
- Enginprime Medical Closes $12M Series A Financing — PR Newswire
Related cases
- Natural secures $30M Series A to create payment rails for AI agents
- Cheche Group’s 35-for-1 share consolidation aims to lift its share price and improve marketability
- Project Q’s €15m Series A underscores rising VC confidence in European defence tech
- Prime Intellect’s $130M Series A values the AI‑agent startup at $1B, underscoring strong investor appetite for enterprise‑grade AI tools
- Hive secures $15 million funding to deploy its ‘silicon brain’ AI chip, promising an 80% reduction in machine operating costs
- Chamath Palihapitiya’s $135M Series A highlights ongoing venture‑capital enthusiasm for AI‑focused coding tools